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ABSTRACT
Objectives Loss of intestinal barrier function plays an
important role in the pathogenesis of inﬂammatory bowel
disease (IBD). Shedding of intestinal epithelial cells is
a potential cause of barrier loss during inﬂammation. The
objectives of the study were (1) to determine whether
cell shedding and barrier loss in humans can be detected
by confocal endomicroscopy and (2) whether these
parameters predict relapse of IBD.
Methods Confocal endomicroscopy was performed in
IBD and control patients using intravenous ﬂuorescein to
determine the relationship between cell shedding and
local barrier dysfunction. A grading system based on
appearances at confocal endomicroscopy in humans was
devised and used to predict relapse in a prospective pilot
study of 47 patients with ulcerative colitis and 11
patients with Crohn’s disease.
Results Confocal endomicroscopy in humans detected
shedding epithelial cells and local barrier defects as
plumes of ﬂuorescein efﬂuxing through the epithelium.
Mouse experiments demonstrated inward ﬂow through
some leakage-associated shedding events, which was
increased when luminal osmolarity was decreased. In
IBD patients in clinical remission, increased cell shedding
with ﬂuorescein leakage was associated with
subsequent relapse within 12 months after
endomicroscopic examination (p<0.001). The sensitivity,
speciﬁcity and accuracy for the grading system to predict
a ﬂare were 62.5% (95% CI 40.8% to 80.4%), 91.2%
(95% CI 75.2 to 97.7) and 79% (95% CI 57.7 to 95.5),
respectively.
Conclusions Cell shedding and barrier loss detected by
confocal endomicroscopy predicts relapse of IBD and has
potential as a diagnostic tool for the management of the
disease.
INTRODUCTION
Defects in intestinal barrier function have been
associated with intestinal inﬂammatory disease.
1e4
In Crohn’s disease (CD) increased intestinal
permeability has been observed in patients and
their relatives.
5e7 Increased intestinal permeability
is also a prognostic indicator of relapse.
8 Further
data implicating barrier defects in disease patho-
genesis is altered expression of tight junction
proteins in patients with CD.
9 Moreover, inhibition
of caveolar endocytosis of occludin out of the tight
junction reduces the tumour necrosis factor (TNF)
induced barrier loss and water secretion.
10
Crucially, primary changes of tight junction
permeability correlate with the severity of experi-
mental colitis.
11 12 Thus an intact intestinal barrier
separating the host from the intestinal contents is
essential for gut health.
The intestinal barrier comprises epithelial cells
and the tight junctions between them. The
epithelial cells migrate from stem cells at the base
of crypts to the small intestinal villi or the surface
of the colon from where they are shed. Our studies
in mice have shown that epithelial cell shedding
leaves a gap or discontinuity in the epithelium that
resolves in most cases in 8e12 min, potentially
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Signiﬁcance of this study
What is already known on this subject?
< Loss of intestinal barrier function plays an
important role in the pathogenesis of inﬂamma-
tory bowel disease (IBD).
< Intestinal epithelial cells are constantly shed
leaving gaps in the epithelial monolayer.
< In the uninﬂamed intestine these gaps are
sealed by a redistribution of tight junction
proteins.
< In the inﬂamed intestine this sealing mechanism
starts to fail with loss of barrier function.
What are the new ﬁndings?
< Loss of intestinal barrier function at sites of cell
shedding can be detected by confocal endomi-
croscopy with intravenous ﬂuorescein.
< The direction of ﬂow through defects in
intestinal epithelium is inﬂuenced by the
osmolarity of the intestinal luminal contents.
< A simple grading system was devised to
summarise the severity of barrier loss and cell
shedding at confocal endomicroscopy in
humans.
< This grading system predicts relapse of IBD over
a 12-month period.
How might it impact on clinical practice in the
foreseeable future?
< Assessment of barrier function and cell shed-
ding by confocal endomicroscopy promises to
be a simple, fast and practical method of
predicting relapse of IBD.
1146 Gut 2012;61:1146e1153. doi:10.1136/gutjnl-2011-300695
Inﬂammatory bowel diseasechallenging the epithelial barrier.
13 These gaps can be detected in
humans by confocal laser endomicroscopy (CLE) using the DNA
ﬂuorescence dye acriﬂavine applied to the mucosal surface of the
intestine.
14 These observations in mice and humans raise the
fundamental biological question of how barrier function is
maintained during epithelial shedding.
15 We have recently
shown that during cell shedding there is a redistribution of
component proteins of the tight junction, including ZO-1 and
occludin, to surround the basolateral surface of the shedding cell
in the form of a funnel, thereby preserving the barrier at the
shedding site.
13 16 We have also shown that cell shedding is
increased by high concentrations of TNF and that in this
stressed situation the intestinal barrier sometimes fails.
14 These
observations suggest that cell shedding might be increased in
inﬂammatory bowel disease (IBD), as has been recently
shown.
17
A number of methods have been developed for the non-
invasive measurement of permeability of the paracellular
pathway of absorption and secretion.
18 These are based on the
absorption of small molecular weight saccharides or chromium-
labelled EDTA and measurement of their appearance in the
urine. They have proved useful in providing an integrated
measurement of barrier function along a long segment of gut.
For example, sucrose absorption measures gastroduodenal
permeability
19 whereas lactulose/mannitol gives a measure of
small intestinal permeability.
20 These techniques have been
successful in the examination of permeability changes in large
populations of patients with IBD.
12 1
More detailed analysis of intestinal epithelial permeability can
be achieved using in vitro techniques on human biopsies
including measurement of transepithelial electrical resistance
and the ﬂux of
3H-mannitol.
22 23 Spatial information on the
location of barrier defects can be obtained with more sophisti-
cated electrical techniques including conductance scanning and
impedance spectroscopy.
24 While these techniques have proved
useful, they do not provide optical information on the sites of
barrier dysfunction.
25 Direct visualisation of barrier defects is
possible with bench top confocal microscopy, which has been
used with success to image the inﬂux of ﬂuorescent probes and
bacteria from the intestinal lumen.
26 27
The aims of this study were, ﬁrst, to determine whether cell
shedding and loss of barrier function in humans can be visualised
by confocal endomicroscopy and, second, whether these
parameters predict relapse of IBD. We ﬁnd that CLE can detect
cell shedding and barrier loss. Furthermore a prospective pilot
study suggests that loss of barrier function detected by CLE
predicts subsequent relapse of IBD.
MATERIAL AND METHODS
Retrospective human study: cell shedding, gap formation and
barrier loss in humans
In a retrospective study of archived CLE images of the terminal
ileum ($30 endomicroscopic images per patient; including
surface epithelial cell layer) 13 patients with IBD in clinical
remission (CD n¼7, ulcerative colitis (UC) n¼6) and 12 control
patients (colon cancer screening) were examined (online
supplementary table 1). Only endomicroscopic images of the
terminal ileum were selected for analysis of local barrier
dysfunction because single epithelial cell layer can be observed in
vertical and horizontal axis and only minimal overlay of cellular
structures occur. Endomicroscopic images were selected based on
the presence of epithelial cell layer and intestinal lumen, and
absence of movement artefacts.
The diagnosis of CD or UC was made on clinical, endoscopic
and histological criteria. There was no signiﬁcant difference in
age or gender between the patient groups (online supple-
mentary table 1). For the patients with CD, remission was
deﬁned by a CD activity index (CDAI) #150 and UC by
a Clinical Activity Index (CAI) #1.
28 29 The control group
comprised patients without any intestinal symptoms (despite
possible occult bleeding conﬁrmed by at least one positive
faecal occult blood test) undergoing endoscopic examination
for colorectal cancer screening. Patients with acute gastroin-
testinal bleeding, coagulopathy (pro-thrombin time <50%
control; partial thromboplastin time >50 s), impaired renal
function (creatinine >1.2 mg/dl), pregnancy or breast feeding,
known allergy to ﬂuorescein or inability to give consent were
excluded.
Prospective pilot study of the predictive value of cell shedding,
gap formation and barrier loss for relapse of IBD
Patients in clinical remission (CDAI#150 and a CAI#1) with
surveillance colonoscopy based on chronic inﬂammation (CD or
UC) within the colon for more than 8 years were offered to
undergo endomicroscopic examination (recruitment period
January 2007 to September 2009). Patients were consecutively
included for analysis if the terminal ileum could be endomicro-
scopically imaged. Inclusion criteria were presence of IBD for
>8 years, absence of macroscopic visible inﬂammatory changes
in the colon or terminal ileum. Exclusion criteria comprised
active acute gastrointestinal bleeding, coagulopathy (pro-
thrombin time <50% control; partial thromboplastin time
>50 s), impaired renal function (creatinine >1.2 mg/dl), preg-
nancy or breast feeding, known allergy to ﬂuorescein or inability
to give consent.
One hundred and thirty-ﬁve patients were screened. The
majority could not be included because of visible inﬂammatory
changes (61) or impossibility to reach the terminal ileum (16).
Fifty-eight patients with IBD (CD¼11, UC n¼47) in clinical and
mucosal remission were ﬁnally analysed (online supplementary
table 2). The Watson grade was determined by examination of
the stored images collected of the terminal ileum at CLE by two
blinded investigators. The patients were prospectively followed
(monthly follow-up) for 12 months using the CDAI in CD
patients and the CAI in UC patients. A ﬂare was deﬁned as
a CDAI>150 and a CAI>3. The identiﬁed patients and their
primary care physicians were invited to participate in the
human studies and informed consent was obtained.
The local ethical committee in Rheinland-Pfalz, Germany,
approved (No. 837.364.07) both the retrospective and prospective
human studies.
Method of CLE and imaging of local barrier dysfunction
For all the human examinations, the Pentax EC3870K endomi-
croscope colonoscope (Pentax, Tokyo) was used, enabling in vivo
surface and subsurface (z-axis) imaging at (sub)cellular resolu-
tion imaging during ongoing video endoscopy. A single intrave-
nous bolus of 5 ml 10% sodium ﬂuorescein (10%dNovartis
Pharma, Germany), was used as a systemic contrast agent and
permeability probe. For all the patients, a conscious sedation
using propofol was administered for colonoscopy.
Physiological and pathophysiological changes within the
lumen and the mucosa of the terminal ileum were inspected for
up to 8 min after injection of ﬂuorescein. Images stacks
(Z-stacks) at a given area were collected from the surface of the
epithelium down to the lamina propria (optical biopsy). The
endomicroscopic images were digitally stored and were analysed
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examination using Pentax software after the procedure.
Endomicroscopic image analysis
For the retrospective study all suitable endomicroscopic images
of the terminal ileum were analysed for the presence of gaps,
microerosions and ﬂuorescein leakage. The overall perimeter of
the villi in each image was calculated using Image J (imagej.
nih.gov.il/) and the amount of affected cells (per perimeter)
was deﬁned (in percentage per optical analysis, which repre-
s e n t saz - s t a c ko fi m a g e si nag i v e nm u c o s a la r e a ) .T h i sd e t a i l e d
analysis was used to devise the Watson grading system (see
below).
Description and validation grading of cell shedding and barrier
loss from endomicroscopic images
An endomicroscopic grading system (Watson grade) was devised
to summarise the degree of local barrier dysfunction in IBD
based on the amount of cell shedding and the intensity of the
luminal ﬂuorescein signal on single good quality images from
four separated ﬁeld of view of the terminal ileum (table 1). Only
areas that were macroscopically normal on the standard colo-
noscopy were selected for endomicroscopic imaging. Great care
was taken to avoid taking images from areas of mucosa with
suction artefacts or endoscopic trauma. Images were graded
according to table 1. The severity of barrier loss and micro-
erosions was discrepant between the images or between the two
blinded investigators the grade was calculated on the most
severe changes.
Confocal laser microscopy of mice
Confocal laser microscopy of mice was performed as previously
described.
26 Fluorescein isothiocyanate (FITC) conjugated
dextran (4 kDa; 20 mg/ml; Sigma) was used as a luminal dye to
detect inward ﬂow. Intravenous Alexa-ﬂuor conjugated dextran
647 (10 kDa; 4 mg/kg; Invitrogen, Paisley, Scotland) was used to
detect outward ﬂow. Hoechst 33342 (5 mg/kg; Invitrogen) was
used as a nuclear dye. See the online supplemental methods ﬁle
for further details.
Statistics
Descriptive data are presented as means6SEM. Comparisons
between the IBD group and normal control patients were made
using t tests and ANOVA tests. Comparison of the percentage of
patients in remission on the basis of their Watson grade was
made using the KaplaneMeier method and analysed by Log-
Rank test. Signiﬁcance level a was set to 5%. Statistics were
computed using the statistical analysis system SAS (release 6.08,
SAS Institute Inc.).
RESULTS
Cell shedding can be detected by CLE using ﬂuorescein as
contrast agent
We have shown previously that CLE can identify cell shedding
events using acriﬂavine applied topically to the mucosal
surface.
14 We now demonstrate that cell shedding can also be
identiﬁed using intravenous ﬂuorescein as the contrast agent.
Intravenous ﬂuorescein enables bright ﬂuorescent imaging of
capillary arcades within the villus (ﬁgure 1A). Prior to shedding,
epithelial cells become permeable to ﬂuorescein (ﬁgure 1B) and
become intensely ﬂuorescent as shedding proceeds (ﬁgure
1CeE). Fluorescent shedding cells can be readily identiﬁed when
viewed en face during confocal endomicroscopy (ﬁgure 1F).
Loss of local barrier function
In the healthy intestine although ﬂuorescein enters the lateral
intercellular spaces up to the apical border, there is no escape
into the lumen, presumably because of constraint by tight
junctions (ﬁgure 1A). Thus when the epithelial barrier is intact
there is no escape of ﬂuorescein in the lumen (ﬁgure 2A).
However at sites of cell shedding ﬂuorescein can sometimes be
seen to enter the gap in the epithelium left by the shedding cell
(ﬁgure 2B). Remarkably at sites of localised loss of barrier
function in the epithelium we observed plumes of ﬂuorescein
efﬂux through epithelial layer at sites of epithelial cell loss. Such
sites of loss of localised barrier function were conﬁned to
between two cells, as ﬂuorescein loss was not seen from
between nearby epithelial cells (ﬁgure 2C). Confocal endomi-
croscopy was also able to identify microerosions, where more
than one cell is lost from a single site and the lamina propria is
exposed to the lumen (ﬁgure 2E). However, the microerosions
were only visible with endomicroscopy, the white light imaging
showed no visible epithelial damage or inﬂammatory change.
The relationship between cell shedding and ﬂuorescein efﬂux
In general it is not possible to follow cellular events with CLE for
more than a few seconds. We therefore performed in vivo
confocal microscopy of cell shedding in mouse small intestine to
deﬁne the relationship between cell shedding and ﬂuorescein
efﬂux more precisely.
16 26 Alexa-ﬂuor 647 conjugated dextrans
were administered to the mouse intravenously as an analogue of
the ﬂuorescein used in our human studies. We found that
instances of ﬂuorescein efﬂux into the lumen from single sites on
the mucosal surface were preceded by cell shedding at that site
(ﬁgure 3A, online supplementary movie).
Direction of ﬂow at sites of loss of local barrier function
There is currently great interest in the hypothesis that loss of
intestinal barrier function enables entry of antigens and other
toxic molecules from the intestinal lumen into intestinal mucosa,
thereby triggering intestinal disease.
30 We therefore analysed
whether the direction of ﬂow at the sites of loss of local barrier
function was always outwards from the intestinal wall into the
lumen as suggested by the observations above using ﬂuorescein-
aided endomicroscopy and the experience from our human study.
Alexa-ﬂuor 647 conjugated dextran was administered intrave-
nously in murine in vivo preparations in order to visualise the
villus vasculature and potential efﬂux from the intestine into the
Table 1 Endomicroscopic grade (Watson grade) for in vivo
identiﬁcation of local barrier dysfunction
Cell shedding Local barrier dysfunction
I. Normal Cell shedding conﬁned to
single cells per shedding
site (eg, ﬁgure 1C or D)
None
II. Functional
defect
Cell shedding conﬁned to
single cells per shedding
site
Fluorescein signal visible in the
intestinal lumen with an intensity
the same or brighter than the
epithelium or ﬂuorescein plumes
out of the epithelium into the lumen
(eg, ﬁgure 2D)
III. Structural
defect
Microerosions in any ﬁeld.
Microerosion is deﬁned when
the lamina propria is exposed
to the lumen with multiple
cells being shed per site
(eg, ﬁgure 2E)
Fluorescein signal visible in the
intestinal lumen with an intensity
the same or brighter than the
epithelium or ﬂuorescein plumes
out of the epithelium into the
lumen (eg, ﬁgure 2E)
See Material and methods.
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Inﬂammatory bowel diseaselumen. At the same time FITC-conjugated dextrans were applied
to the luminal surface in a solution of 300 mOsm/l in order to
assess inﬂux across the intestinal barrier. Fields of view were
analysed for cell shedding by the movement of Hoechst 33342
stained nuclei out of a villus and into the luminal compartment.
We observed four patterns of ﬂow at the gaps created by shedding
cells (ﬁgure 3BeE). Examples of outward ﬂow could be observed
in which there was a continuous ﬂow of intravenous dye (red)
from the villus vasculature but there was no entry of the luminal
dye (green) (ﬁgure 3B). Conversely we could observe instances in
which there was entry of the luminal dye across the epithelial
layer to the capillary arcade without efﬂux of the intravenous dye
(ﬁgure 3C). We also observed instances where there was simul-
taneous inﬂux and efﬂux of dyes (ﬁgure 3D) and instances where
although there was an epithelial gap there was neither inﬂux nor
efﬂux of dyes (ﬁgure 3E).
The proportion of cell shedding events when the small
intestinal epithelium was bathed in 300 mOsm/l in which there
was leakage of dye in either direction was 18.860.9% (ﬁgure
4A), 17.566.0% of which was inward, 76.3%610.3% was
outward and 666.3% was in both directions (ﬁgure 4B). It
should be noted that cell shedding events were only quantiﬁed
when the origin and destination of the shed cell could be clearly
observed within a z-stack of images over time.
We then asked if the direction of ﬂow was inﬂuenced by the
osmolarity of the luminal contents. Reduction of luminal
Figure 2 Loss of barrier function
visualised by confocal endomicroscopy.
(A) Intact barrier function with no
escape of ﬂuorescein into the gut lumen
(arrow). (B) Fluorescein in the gap in
the epithelium left by a shedding cell
(arrow). Cellular debris from the
shedding cell can be seen in the lumen.
(C) efﬂux of ﬂuorescein out of blood
vessels (block arrow) into the lateral
intercellular space. Efﬂux into the lumen
is constrained at the apical border
(block arrows). A plume of ﬂuorescein
efﬂuxing through the gap left behind
a shedding cell (line arrow). (D)
Multiple sites of efﬂux of ﬂuorescein
through the epithelium into gut lumen
(arrows). Note the increased
ﬂuorescence in the gut lumen. (E)
Microerosion (arrow) where more than
one epithelial cell has been lost at one
site exposing a capillary to the lumen.
Note the functional relevance of this
lesion as there is efﬂux of ﬂuorescein
into the lumen.
Figure 1 Confocal endomicroscopic
imaging of epithelial cell shedding in the
terminal ileum. (A) Fluorescein images
capillaries beneath epithelial cells (block
arrow) and the lateral intracellular space
between epithelial cells (line arrow). (B)
Epithelial cells become permeable to
ﬂuorescein prior to shedding (line
arrow). (CeE) Fluorescein ﬂuorescence
signal is intense as shedding cells move
out of the epithelial monolayer. (F)
Intensely ﬂuorescent shedding epithelial
cells seen en face.
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Inﬂammatory bowel diseaseosmolarity to 246 mOsm/l increased the abundance of leakage-
associated cell shedding (p<0.05) (ﬁgure 4A). Reduction in
luminal osmolarity relative to plasma would be predicted to
increase the driving force favouring inward ﬂow. Appropriately
we observed a substantial reduction in the proportion with
outward ﬂow (p<0.05) a non-signiﬁcant increase in the
proportion of shedding events with inward ﬂow, and a signiﬁ-
cant increase in the proportion with both inward and outward
ﬂow (p<0.01) (ﬁgure 4B).
Incidence of gaps, ﬂuorescein leakage and microerosions in
patients with IBD
We evaluated in a retrospective study the incidence of epithelial
gaps, showed signiﬁcantly more epithelial gaps, microerosions
and ﬂuorescein leakage in patients with UC and CD compared
with controls (online supplemental table 1). We have shown
previously that cell shedding causes discontinuities in the
epithelium called ‘gaps’.
13 14 Images were only taken from areas
of the colon or terminal ileum that were not inﬂamed or
damaged on conventional colonoscopic views. There were
signiﬁcantly more epithelial gaps, microerosions and ﬂuorescein
leakage in patients with UC and CD than control patients (table
2) (p<0.0001), indicating increased cell shedding and barrier loss
in IBD patients. There was no signiﬁcant difference between the
endomicroscopic features of local barrier dysfunction in patients
with CD and UC.
Prospective pilot study of the predictive value of cell shedding,
gap formation and barrier loss for relapse of IBD
In order to quantify cell shedding and local barrier dysfunction
at CLE we developed a grade based on the human and animal
experiments described above and validated the grade by its
prediction of subsequent relapse of CD and UC (table 1). A
Watson grade of I is normal, physiological cell shedding deﬁned
as single cells being shed. In preliminary versions of the grade we
found that the number of cells being shed did not predict
subsequent relapse, providing there was no ﬂuorescein leakage or
microerosions created by multiple cells being shed from a single
site. Thus the number of shedding cells being shed is not part of
Watson grade I. Evidence of loss of barrier function when ﬂuo-
rescein leaks into the lumen is designated Watson grade II
(functional defect). Microerosions caused by multiple epithelial
cells being shed from a single site revealing the lamina propria to
the lumen is designated Watson grade III (structural defect).
To validate the Watson grade we performed a prospective pilot
study. Fifty-eight patients with IBD in complete clinical
Figure 3 (A) Localised ﬂuorescein leak is preceded by cell shedding. Intravenous Alexa-dextran 647 (MW 10000) shown in red and Hoechst 33342
labelled nuclei in blue. Images at 0, 5, 15 and 28 min relative to the start of cell shedding. (BeE) Dextran movement across small intestinal epithelia.
Luminal FITC-dextran (MW 4000) shown in green. Intravenous Alexa-dextran 647 (MW 10000) shown in red and combined images shown with
Hoechst 33342 labelled nuclei. Dextran leakage from circulation into lumen in an outward direction (BeD), from lumen in an inward direction (EeG), in
both inward and outward directions (HeJ) and no movement of inward or outward dextran (KeM).
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Inﬂammatory bowel diseaseremission with absence of inﬂammatory changes on white light
endoscopy were examined by confocal endomicroscopy. No
serious or ﬂuorescein or device related adverse events occurred
during the prospective study. The endomicroscopic image grade
was determined after the procedure. A total of 232 endomicro-
scopic images (four per patient) were judged. Cohen’s k coefﬁ-
cient was 0.87, which shows a strong agreement between the
two blinded observers.
We found that 24 patients suffered a ﬂare of their disease
within 12 months after the confocal endomicroscopic exami-
nation. KaplaneMeier analysis was undertaken of the relapse for
the 12-month period after CLE following stratiﬁcation by their
Watson grade. Patients who subsequently had a ﬂare of their
disease had signiﬁcantly more ﬂuorescein leakage and micro-
erosions thus a higher Watson grade than patients who did not
suffer a ﬂare p<0.001 (table 3, ﬁgure 4C). The sensitivity,
speciﬁcity and accuracy for the Watson grades II/III to predict
a ﬂare were 62.5% (95% CI 40.8 to 80.4), 91.2% (95% CI 75.2 to
97.7) and 79% (95% CI 57.7 to 95.5), respectively.
DISCUSSION
In this study we show that ﬂuorescein-aided CLE can identify
cells in the process of being shed. Remarkably, efﬂux of ﬂuo-
rescein can be seen at a proportion of sites of cell shedding
providing for the ﬁrst time direct visualisation of local barrier
defects in human patients. Studies in mice demonstrate that
both an efﬂux of intravenous dyes and an inﬂux of luminal dyes
can occur at sites of cell shedding. Furthermore, studies in mice
show that the proportion of sites with inﬂux or efﬂux is inﬂu-
enced by the osmotic gradient across the epithelium. Finally, we
show that local defects in barrier function are increased and
predict relapse in patients with IBD.
The morphology of the shedding cells in humans as demon-
strated by CLE is remarkably similar to that observed in mice
and is compatible with apoptosis.
16 26 31 Using intravenous
administration of ﬂuorescein we assessed the integrity of the
epithelial barrier with CLE. In healthy individuals ﬂuorescein
does not enter the lumen though ﬂuorescein can be seen tracking
up the lateral intercellular space to the tight junctions (ﬁgure 1A,
B and ﬁgure 2AeC).
To our knowledge CLE is the only method that can identify
sites of barrier loss at a microscopic level in real time. Although
there are a number of physiological techniques to identify
localised loss of barrier function they are not applicable to
routine clinical usage.
18 22e25 32 33 The fact that CLE is combined
with routine conventional colonoscopy makes it an attractive
and convenient diagnostic methodology for routine clinical use.
Flow of ﬂuorescein from the bowel wall into the lumen is easy
to detect as the luminal ﬂow becomes ﬂuorescent even if the site
of barrier loss is not identiﬁed.
A recurrent theme in the current consensus view of the
pathogenesis of IBD is that inward ﬂow of antigens and
Figure 4 Analysis of loss of local
barrier function and prediction of
relapse of inﬂammatory bowel disease
(IBD). Dextran movement (Luminal
FITC-dextran (MW 4000) and
intravenous Alexa-dextran 647 (MW
10000)) through small intestinal
epithelium at the site of epithelial cell
shedding from luminal perfusion
solutions of either 300 mOsm/l (black)
and 246 mOsm/l (grey) solutions. (A)
Percentage of events that show no
dextran movement (sealed) and dextran
leakage (leakage) in either the inward or
the outward directions. (B) Percentage
movement of dextran in an inward,
outward or inward and outward
direction from the leakage group.
*p<0.05, **p<0.01, error bars show
SEM (n¼4 mice per group). (C)
KaplaneMeier plot of relapse of IBD
patients over 12 months after confocal
laser endomicroscopy stratiﬁed
according to their Watson grade.
Table 2 Endomicroscopic features of local barrier dysfunction in IBD
and controls
Crohn’s disease Ulcerative colitis Controls p Value*
Patients (N) 7 6 12 NA
Average number of
optical biopsies
33.8 42.1 36.6 NS
Gaps (%) 8.661.3 8.262.1 2.560.9 <0.0001
Microerosions (%) 1.860.6 1.460.7 0.160.03 <0.0001
Fluorescein leakage
(% of optical biopsies)
32.469.3 28.967.2 4.263.1 <0.0001
% Gaps and microerosions refer the proportion of the perimeter of epithelial surface with
gaps or microerosions.
*p Value: t test IBD patients (Crohn’s disease and ulcerative colitis) versus controls.
IBD, inﬂammatory bowel disease; NA, not applicable; NS, not signiﬁcant.
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Inﬂammatory bowel diseasemicrobes from the intestinal lumen into the bowel wall is of
importance.
4 34 35 Our CLE studies in humans are only able to
demonstrate ﬂow in the opposite direction; in other words from
within the bowel wall into the lumen. However we hypoth-
esised that if there are sites of outward ﬂow there might also be
sites of inward ﬂow, which would be more pathologically rele-
vant, and that outward ﬂow detected at CLE might be a marker
of inward ﬂow. We employed our mouse model of cell shedding
to investigate further the local barrier defects at sites of cell
shedding.
26 Using intravenous Alexa-dextran 647 we showed
that the localised barrier defects that we observed during human
CLE could be the result of cell shedding (ﬁgure 3A). Furthermore
we demonstrate that incomplete sealing of the site of cell
shedding can result in outward ﬂow, inward ﬂow or bidirectional
ﬂow and that the osmotic gradients between the lumen and the
epithelial monolayer are a factor that determines the direction of
ﬂow through the barrier defect (ﬁgures 3 and 4). The other
factors that may determine the direction of ﬂow through local
barrier defects are hydrostatic pressure with the intestinal wall,
villus contraction and peristalsis.
36e38
We have demonstrated that while majority of shedding sites
are sealed when the luminal contents are iso-osmolar with
serum, the proportion of sealed sites is reduced by an inwardly
directed osmotic ﬂow (ﬁgure 4A). We also show that the direc-
tion of ﬂow through epithelial barrier defects is inﬂuenced by
luminal osmolarity. Imposing an inwardly directed osmotic
gradient reduces outward ﬂow and increases bidirectional ﬂow,
which we interpret as free diffusion back and forth (ﬁgure 4B).
From these observations we conclude that the direction of ﬂow
through the epithelium is unstable and highly dependent on
local osmotic and pressure gradients. While the luminal contents
of the intestine are classically regarded as iso-osmolar, there are
likely to be areas, particularly in the upper small intestine, where
mixing and transepithelial ion transport has not achieved iso-
osmolarity within the lumen. Our ﬁnding that loss of barrier
function predicts relapse (table 3, ﬁgure 4C) supports our
conclusion that outward ﬂow of ﬂuorescein into the intestinal
lumen identiﬁed by CLE is a marker of loss of barrier function
where inward ﬂow of antigens, toxins and microbes, activating
the mucosal immune system also occurs.
CLE identiﬁes three related parameters, cell shedding, ﬂow of
ﬂuorescein into the intestinal lumen and the development of
microerosions, which we combined into a simple grading system
to predict relapse of with IBD in remission. In early versions of
our grading system we were surprised that the abundance of cell
shedding alone did not predict relapse. Only cell shedding with
the addition of barrier loss was predictive. This is in accord with
our earlier observations
13 14 26 that the complete sealing of gaps
is achieved if inﬂammatory cytokine concentrations are low
(ﬁgure 4A). The presence of microerosions (loss of more than one
adjacent epithelial cell from a single site) was also predictive of
relapse. Microerosions without loss of barrier function were
uncommon so the presence of microerosions is likely to be
a marker of loss of barrier function.
In a prospective study we examined 58 patients with IBD and
complete mucosal healing as deﬁned by white light endoscopy.
The presence of functional (ﬂuorescein leakage) or structural
defects (microerosions) could be readily identiﬁed in the terminal
ileum of patients using ﬂuorescein-aided endomicroscopy and
predicted relapse of IBD. Patients with local barrier dysfunction
(Watson II/III) were signiﬁcantly more likely to relapse
(p<0.001) compared with patients where healing was also
conﬁrmed endomicroscopically (Watson grade I). It is of interest
that we found changes in the terminal ileum of patients with
UC that predict relapse even though classically UC does not
include the terminal ileum. We are investigating this ﬁnding
further with additional studies. The data from this pilot study
provides data to enable the design of a clinical trial to conﬁrm
whether CLE can accurately predict the relapse of patients with
UC or CD.
In conclusion, these studies suggest CLE might be a useful
tool for the management of IBD. The prediction and prevention
of relapse of IBD is a major goal of current IBD clinical
research.
39 Our observations suggest that CLE might be a useful
and convenient tool to predict relapse and adds to the growing
body of evidence that loss of barrier function plays a major role
in the pathogenesis of IBD.
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